Literature DB >> 2605687

Metabolism of gentiopicroside (gentiopicrin) by human intestinal bacteria.

A I el-Sedawy, M Hattori, K Kobashi, T Namba.   

Abstract

As a part of our studies on the metabolism of crude drug components by intestinal bacteria, gentiopicroside (a secoiridoid glucoside isolated from Gentiana lutea), was anaerobically incubated with various defined strains of human intestinal bacteria. Many species had ability to transform it to a series of metabolites. Among them, Veillonella parvula ss parvula produced five metabolites, which were identified as erythrocentaurin, gentiopicral, 5-hydroxymethylisochroman-1-one,5-hydroxymethylisochromen-1- one and trans-5,6-dihydro-5-hydroxymethyl-6-methyl-1H,3H-pyrano[3,4-c]pyra n-1-one.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2605687     DOI: 10.1248/cpb.37.2435

Source DB:  PubMed          Journal:  Chem Pharm Bull (Tokyo)        ISSN: 0009-2363            Impact factor:   1.645


  4 in total

1.  Pharmacokinetics and tissue distribution of gentiopicroside following oral and intravenous administration in mice.

Authors:  Chang-Hong Wang; Zheng-Tao Wang; S W Annie Bligh; Kenneth N White; Christopher J Branford White
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2004 Jul-Sep       Impact factor: 2.441

2.  Microbial biotransformation of gentiopicroside by the endophytic fungus Penicillium crustosum 2T01Y01.

Authors:  Wen-Liang Zeng; Wan-Kui Li; Han Han; Yan-Yan Tao; Li Yang; Zheng-Tao Wang; Kai-Xian Chen
Journal:  Appl Environ Microbiol       Date:  2013-10-18       Impact factor: 4.792

3.  Preventive effect of Agnucastoside C against Isoproterenol-induced myocardial injury.

Authors:  Sunanda Panda; Anand Kar; Sagarika Biswas
Journal:  Sci Rep       Date:  2017-11-23       Impact factor: 4.379

Review 4.  Potential roles of gut microbes in biotransformation of natural products: An overview.

Authors:  Yucui Zhao; Xinqin Zhong; Junyuan Yan; Congying Sun; Xin Zhao; Xiaoying Wang
Journal:  Front Microbiol       Date:  2022-09-29       Impact factor: 6.064

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.